References
Alloni A, Pellegrini C, Ragni T, Goggi C, D’Armini AM, Rinaldi M, Vigano M (2004) Heart transplantation in patients with amyloidosis: single-center experience. Transplant Proc 36:643– 644
Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, La- Valley M, O’Hara C, Arkin CF, Wright DG, Skinner M (1998) Dose-intensive melphalan with blood stem-cell support for the treatment ao AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 91:3662–3670
Comenzo RL, Gertz MA (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99:4276–4282
Dubrey SW, Burke MM, Hawkins PN, Banner NR (2004) Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 23:1142–1153
Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidosis. N Engl J Med 337:898–909
Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, Litzow MR (2002) Stem cell transplantation for the management of primary systemic amyloidosis. Am J M 113:549–555
Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN (2006) Sequential cardiac and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107:1227–1229
Hosenpud JD, DeMarco T, Frazier OH, Griffith BP, Uretsky BF, Menkis AH, O’Connell JB, Olivari MT, Valantine HA (1991) Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 84:338–343
Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:542–543
Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1999) Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 93:1062–1066
Mohty M, Albat B, Fegueux N, Rossi JF (2001) Autologous peripheral blood stem cell transplantation following heart transplantation for primary systemic amyloidosis. Leuk Lymph 41:221–223
Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H (2004) High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of AL amyloidosis: a single centre prospective phase II study. Br J Haematol 127:543–551
Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O’Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Int Med 140:85–93
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perz, J.B., Kristen, A.V., Rahemtulla, A. et al. Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol 95, 671–674 (2006). https://doi.org/10.1007/s00392-006-0439-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-006-0439-y